

# Pneumothorax Treatment Market 2026

<https://marketpublishers.com/r/P61C0264CDEAEN.html>

Date: December 2025

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: P61C0264CDEAEN

## Abstracts

The Pneumothorax Treatment Market was valued at in and is anticipated to reach by , at a CAGR of 0.045 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Pneumothorax Treatment Market.

This report delivers a comprehensive overview of the Pneumothorax Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pneumothorax Treatment Market. The Pneumothorax Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Pneumothorax Treatment Market Scope:

By Medication

Local Anesthetics

Opiate Analgesics

Benzodiazepines

Antibiotics

Others

#### By Treatment type

Pleurectomy

Bullectomy

Pleurodesis

Others

#### By Indication

Primary spontaneous pneumothorax Infection

Secondary spontaneous pneumothorax Infection

Injury-related pneumothorax Infection

Tension pneumothorax Infection

Others

#### By End-user

Hospitals

Clinics

Ambulatory Surgery Centers

Others

## By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

## Key Players

Pfizer Inc.

Fresenius Kabi USA

Akorn, Inc.

Piramal Critical Care

Baxter Healthcare Corporation

Valeant Pharmaceuticals North America LLC

Teva Pharmaceuticals USA, Inc.

Comed Chemicals Ltd.

UCB, Inc.

Midas Pharma GmbH

## Major Highlights

This report delivers a comprehensive overview of the Pneumothorax Treatment Market,

with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pneumothorax Treatment Market. The Pneumothorax Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

#### Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

#### Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. MARKET DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Market Snippet by Medication
- 3.2. Market Snippet by Treatment type
- 3.3. Market Snippet by Indication
- 3.4. Market Snippet by End user
- 3.5. Market Snippet by Distribution channel
- 3.6. Market Snippet by Region

### **4. MARKET DYNAMICS**

#### 4.1. Market Impacting Factors

##### 4.1.1. Drivers

4.1.1.1. Advancement in the diagnosis of pneumothorax is expected to drive market growth.

##### 4.1.2. Restraints:

4.1.2.1. Lack of awareness regarding pneumothorax infections in emerging countries are expected to hamper the market growth.

##### 4.1.3. Opportunity

##### 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Supply Chain Analysis
- 5.2. Pricing Analysis
- 5.3. Unmet Needs

### **6. COVID-19 ANALYSIS**

- 6.1. Analysis of Covid-19 on the Market

- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

## **7. BY MEDICATION**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication
  - 7.1.2. Market Attractiveness Index, By Medication Segment
- 7.2. Local Anesthetics\*
  - 7.2.1. Lidocaine hydrochloride (Xylocaine, LidaMantle, Anestacon)
  - 7.2.2. Others
  - 7.2.3. Introduction
  - 7.2.4. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 7.3. Opiate Analgesics
  - 7.3.1. Fentanyl citrate (Sublimaze)
  - 7.3.2. Morphine (Astramorph, Infumorph 200, MS Contin, Oramorph SR)
  - 7.3.3. Others
- 7.4. Benzodiazepines
  - 7.4.1. Midazolam
  - 7.4.2. Lorazepam (Ativan)
  - 7.4.3. Others
- 7.5. Antibiotics
  - 7.5.1. Doxycycline (Vibramycin, Vibra-Tabs, Doryx)
  - 7.5.2. Cefazolin (Kefzol)
  - 7.5.3. Others
- 7.6. Others

## **8. BY TREATMENT TYPE**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  - 8.1.2. Market Attractiveness Index, By Treatment Type Segment

## 8.2. Pleurectomy\*

### 8.2.1. Introduction

8.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

## 8.3. Bullectomy

## 8.4. Pleurodesis

## 8.5. Others

# 9. BY INDICATION

## 9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

9.1.2. Market Attractiveness Index, By Indication Segment

## 9.2. Primary spontaneous pneumothorax Infection\*

### 9.2.1. Introduction

9.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

## 9.3. Secondary spontaneous pneumothorax Infection

## 9.4. Injury-related pneumothorax Infection

## 9.5. Tension pneumothorax Infection

## 9.6. Others

# 10. BY END-USER

## 10.1. Introduction

10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

10.1.2. Market Attractiveness Index, By End-user Segment

## 10.2. Hospitals\*

### 10.2.1. Introduction

10.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

## 10.3. Clinics

## 10.4. Ambulatory Surgery Centers

## 10.5. Others

# 11. BY DISTRIBUTION CHANNEL

## 11.1. Introduction

11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

- 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
- 11.2. Hospital Pharmacies\*
  - 11.2.1. Introduction
  - 11.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 11.3. Retail Pharmacies
- 11.4. Online Pharmacies
- 11.5. Others

## **12. BY REGION**

- 12.1. Introduction
  - 12.1.1. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  - 12.1.2. Market Attractiveness Index, By Region
- 12.2. North America
  - 12.2.1. Introduction
  - 12.2.2. Key Region-Specific Dynamics
  - 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication
  - 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  - 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  - 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  - 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  - 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    - 12.2.8.1. U.S.
    - 12.2.8.2. Canada
    - 12.2.8.3. Mexico
- 12.3. Europe
  - 12.3.1. Introduction
  - 12.3.2. Key Region-Specific Dynamics
  - 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication
  - 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  - 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  - 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  - 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  - 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    - 12.3.8.1. Germany
    - 12.3.8.2. U.K.
    - 12.3.8.3. France

12.3.8.4. Italy

12.3.8.5. Spain

12.3.8.6. Rest of Europe

12.4. South America

12.4.1. Introduction

12.4.2. Key Region-Specific Dynamics

12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication

12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12.4.8.1. Brazil

12.4.8.2. Argentina

12.4.8.3. Rest of South America

12.5. Asia Pacific

12.5.1. Introduction

12.5.2. Key Region-Specific Dynamics

12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication

12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12.5.8.1. China

12.5.8.2. India

12.5.8.3. Japan

12.5.8.4. Australia

12.5.8.5. Rest of Asia Pacific

12.6. Middle East and Africa

12.6.1. Introduction

12.6.2. Key Region-Specific Dynamics

12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medication

12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

## **13. COMPETITIVE LANDSCAPE**

- 13.1. Key Developments and Strategies
- 13.2. Company Share Analysis
- 13.3. Product Benchmarking
- 13.4. List of Key Companies to Watch

## **14. COMPANY PROFILES**

- 14.1. Pfizer Inc.\*
  - 14.1.1. Company Overview
  - 14.1.2. Product Portfolio and Description
  - 14.1.3. Key Highlights
  - 14.1.4. Financial Overview
- 14.2. Fresenius Kabi USA
- 14.3. Akorn, Inc.
- 14.4. Piramal Critical Care
- 14.5. Baxter Healthcare Corporation
- 14.6. Valeant Pharmaceuticals North America LLC
- 14.7. Teva Pharmaceuticals USA, Inc.
- 14.8. Comed Chemicals Ltd.
- 14.9. UCB, Inc.
- 14.10. Midas Pharma GmbH (\*LIST NOT EXHAUSTIVE)

## **15. DATAM INTELLIGENCE**

- 15.1. Appendix
- 15.2. About Us and Applications
- 15.3. Contact Us

## I would like to order

Product name: Pneumothorax Treatment Market 2026

Product link: <https://marketpublishers.com/r/P61C0264CDEAEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P61C0264CDEAEN.html>